SOURCE: Cerecor Inc.

Cerecor Inc.

February 16, 2012 09:30 ET

Cerecor Announces Development Advisory Board

BALTIMORE, MD--(Marketwire - Feb 16, 2012) - Cerecor Inc., a biopharmaceutical company focused on the discovery, development and commercialization of prescription pharmaceuticals whose primary activity is in the human nervous system, today announced the members of its Development Advisory Board to oversee the clinical development of its FP01 program, established to supplement its management team.

"We believe that now is an opportune time in the company's life to announce this world-class board of strategic, development advisors on whom we routinely call for advice in our cough program," stated Blake M Paterson, M.D., Co-founder & CEO of Cerecor. "We welcome this distinguished group of highly accomplished professionals to the Cerecor team and believe they will provide inestimable value to our cough program as we continue to make progress in the coming months and years." Dr. Brendan Canning, Chair of the Development Advisory Board, commented, "The company has assembled an extraordinary group of opinion leaders in pulmonary medicine, clinical research and drug discovery. Combined with their internal expertise and an outstanding management team, Cerecor is ideally positioned to progress FP01 as the first safe and effective treatment for cough in over half a century."

Development Advisory Board

The Development Advisory Board of the company is chaired by Brendan Canning, PhD, who is a member of the JHMI faculty and a world authority in cough, and the first to make the observation of FP01's effects in cough. He is credited with many discoveries related to the neurophysiological mechanisms underlying the initiation of cough and is the editor-in-chief of the journal Cough. Other members of the board include Peter Dicpinigaitis, MD (Professor of Clinical Medicine at the Albert Einstein College of Medicine, in New York), Ian Paul, MD (Professor of Pediatrics and Public Health Sciences at Penn State University), Surinder Birring, MD (Consultant Respiratory Physician and Honorary Senior Lecturer, Department of Respiratory Medicine, King's College Hospital, London, England), Robert A. Wise, MD (Professor of Medicine Johns Hopkins Medicine, Pulmonary and Critical Care Medicine), and Mark Ginski, PhD (Director, UMBC Biotechnology Board, UMB Pharmaceutical Sciences PhD Review Committee, CMC expert).

About Cerecor Inc.

Cerecor Inc. ("Cerecor" or the "Company") is a biopharmaceutical company focused on the discovery, development and commercialization of prescription pharmaceuticals whose primary activity is in the human nervous system. Cerecor is focused on translational medicine -- the accelerated transfer of technology from the academic laboratory to early human trials, with the goal of rapid commercialization. We acquire rights to early stage therapeutic technologies ("assets") from universities, finance and manage the development of these assets into drug candidates (to first major milestone or value inflection point) and then either commercialize or outlicense the asset. www.cerecor.com

Contact Information

  • For More Information:

    Jeff Ramson
    ProActive Capital Resources Group
    (646) 863-6341